Clinical Trial Search

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 98.0 percentage of participants

Primary: Incidence of Inhibitory Antibodies Against FIX Defined as Titre Above or Equal to 0.6 BU (Bethesda Units) — 0; 0; 0; 0 Patients with inhibitory antibodies

Primary: Anti-pneumococcal Antibody Concentrations — 3.43; 0.33; 3.60; 6.86 μg/mL

Primary: Change in HbA1c — -1.51; -1.78; -1.11; -1.37 percentage of HbA1c — p=<0.0001

Primary: Percent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis — -43.8; -70.1; -4.3 percent change — p=<0.0001

Primary: Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 12 — -10.7; -15.1 lesion count — p=< 0.0001

Primary: Change in Average Daily Pain Score as Measured Using a Pain Intensity Rating (NRS) — -0.3; -0.5 units on a scale — p=0.56

Primary: Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE) — 94; 94 participants

Primary: Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population — 83.8; 85.2 Percentage of participants

Primary: Change From Baseline to 26 Weeks in Hemoglobin A1c (HbA1c) — -1.73; -1.36 percentage of HbA1c

Primary: Body Composition — 31.84; 33.4; 30.75; 32.12 percentage of fat mass

Primary: Overall Survival — 8.9; 10.5 month — p=0.24

Primary: Annualized Rate of On-treatment Exacerbations Per Year — 0.93 Exacerbations per year

Primary: Number of Patients With Incidence of Delirium Across All Patients at Baseline and Over Post-operative Days 1-3 — 85; 43 Participants — p=0.912

Primary: Progression-free Survival (PFS) — 5.72; 5.39 months